These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32807727)

  • 1. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
    Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
    Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F; Hussain MHA; Tombal B; Fizazi K; Sternberg CN; Crawford ED; Nordquist LT; Bögemann M; Tutrone R; Shore ND; Belkoff L; Fralich T; Jhaveri J; Srinivasan S; Li R; Verholen F; Kuss I; Smith MR
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
    Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
    J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
    Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N
    Eur Urol Oncol; 2024 Oct; 7(5):1097-1104. PubMed ID: 38523017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.
    Wong RL; Duong MT; Tangen CM; Agarwal N; Cheng HH; Vogelzang NJ; Hussain M; Thompson IM; Quinn DI; Yu EY
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):486-493. PubMed ID: 32055002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population.
    Gupta A; Hussain SM; Sonthwal N; Chaturvedi H
    J Cancer Res Ther; 2021; 17(2):389-392. PubMed ID: 34121682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
    Abdel-Rahman O; Cheung WY
    Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.
    Masson-Lecomte A; Guy L; Pedron P; Bruyere F; Rouprêt M; Nsabimbona B; Dahan M; Hoffman P; Salomon L; Vordos D; Hoznek A; Le Corvoisier P; Morel P; Abbou C; de la Taille A
    World J Urol; 2013 Apr; 31(2):339-43. PubMed ID: 22527669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
    Gebrael G; Sayegh N; Thomas VM; Chigarira B; Tripathi N; Jo YJ; Li H; Sahu KK; Srivastava A; McFarland T; Maughan BL; Swami U; Agarwal N
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):279-282. PubMed ID: 37460732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone naïve prostate cancer: predicting and maximizing response intervals.
    Moul JW
    Asian J Androl; 2015; 17(6):929-35; discussion 933. PubMed ID: 26112479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide.
    Tashiro Y; Akamatsu S; Ueno K; Kamoto T; Terada N; Hida T; Kurahashi R; Kamba T; Saito A; Lee T; Morita S; Kobayashi T
    Int J Clin Oncol; 2024 Oct; 29(10):1564-1573. PubMed ID: 39153094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
    Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.